Despite the lack of a venture arm, since 2007 Celgene Corp. (NASDAQ:CELG) has provided venture funding to at least eight companies and done six deals in which it took an equity stake. With eight of these companies, Celgene received an option to acquire programs or the company itself. (A) Acquired by Shire plc (LSE:SHP; NASDAQ:SHPG) in 2012; Source: BCIQ: BioCentury Online Intelligence; company press releases and websites


Transaction description

Financial terms

Status at time of deal


Acceleron Pharma Inc.

Jointly develop and commercialize Acceleron's cancer compound ACE-011 and option to jointly develop and commercialize three undisclosed discovery programs for cancer and cancer-related

$50M up front, including a $5M equity investment; $510M in milestones for ACE-011, plus tiered royalties; Celgene will also purchase a minimum of $7M in an IPO; $437M in milestones for each of the three undisclosed programs

Ph Ib